Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (SHE:300452)
China · Delayed Price · Currency is CNY 14.11
0.00 (0.00%)
Apr 30, 2026, 3:04 PM CST
SHE:300452 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 956.32 | 942.8 | 871.93 | 827.17 | 694.08 | 607.27 |
Other Revenue | - | - | 10.64 | 12.09 | 10.44 | 9.43 |
| 956.32 | 942.8 | 882.57 | 839.26 | 704.53 | 616.71 | |
Revenue Growth (YoY) | 7.12% | 6.82% | 5.16% | 19.12% | 14.24% | 16.10% |
Cost of Revenue | 652.77 | 643.43 | 609.34 | 573.93 | 495.28 | 438.93 |
Gross Profit | 303.54 | 299.36 | 273.23 | 265.33 | 209.24 | 177.78 |
Selling, General & Admin | 69.2 | 68.33 | 63.54 | 60 | 51.13 | 52.05 |
Research & Development | 40.61 | 42.27 | 40.95 | 41.95 | 34.43 | 26.8 |
Other Operating Expenses | -3.88 | -5.24 | -1.69 | 2 | 2.72 | 5.85 |
Operating Expenses | 105.93 | 105.36 | 102.8 | 103.99 | 88.23 | 84.7 |
Operating Income | 197.62 | 194 | 170.43 | 161.34 | 121.01 | 93.08 |
Interest Expense | - | - | -12.73 | -4.3 | -1.21 | -1.2 |
Interest & Investment Income | 15.39 | 13.35 | 20.18 | 11.84 | 9.05 | 6.93 |
Currency Exchange Gain (Loss) | - | - | 1.88 | 0.37 | 2.56 | -0.28 |
Other Non Operating Income (Expenses) | -15.27 | -13.57 | -0.42 | -0.41 | -0.38 | -0.39 |
EBT Excluding Unusual Items | 197.74 | 193.79 | 179.34 | 168.84 | 131.02 | 98.14 |
Impairment of Goodwill | - | - | -39.13 | - | - | -6.13 |
Gain (Loss) on Sale of Investments | 3.33 | 5.92 | -3.13 | 8.51 | -2.62 | 1.74 |
Gain (Loss) on Sale of Assets | -1.07 | -0.96 | 0.11 | -0.01 | -0.27 | -2.96 |
Asset Writedown | -0.06 | -0.06 | -0 | -1.02 | -0.01 | - |
Other Unusual Items | - | - | 5.17 | 9.5 | 8.29 | 5.89 |
Pretax Income | 199.94 | 198.68 | 142.36 | 185.82 | 136.4 | 96.68 |
Income Tax Expense | 25.95 | 25.51 | 21.83 | 21.2 | 5.47 | 11.14 |
Earnings From Continuing Operations | 173.99 | 173.17 | 120.52 | 164.62 | 130.93 | 85.54 |
Minority Interest in Earnings | 2.44 | 3.38 | -1.1 | -3.09 | -0.23 | 3.72 |
Net Income | 176.44 | 176.55 | 119.42 | 161.54 | 130.71 | 89.25 |
Net Income to Common | 176.44 | 176.55 | 119.42 | 161.54 | 130.71 | 89.25 |
Net Income Growth | 51.08% | 47.84% | -26.07% | 23.58% | 46.45% | -4.99% |
Shares Outstanding (Basic) | 235 | 235 | 234 | 234 | 233 | 235 |
Shares Outstanding (Diluted) | 242 | 242 | 234 | 241 | 233 | 235 |
Shares Change (YoY) | 2.01% | 3.28% | -2.88% | 3.29% | -0.63% | 1.93% |
EPS (Basic) | 0.75 | 0.75 | 0.51 | 0.69 | 0.56 | 0.38 |
EPS (Diluted) | 0.73 | 0.73 | 0.51 | 0.67 | 0.56 | 0.38 |
EPS Growth | 48.10% | 43.14% | -23.88% | 19.64% | 47.37% | -6.79% |
Free Cash Flow | 169.27 | 151.26 | 90.39 | 77.38 | 65.5 | 72.35 |
Free Cash Flow Per Share | 0.70 | 0.63 | 0.39 | 0.32 | 0.28 | 0.31 |
Dividend Per Share | - | - | 0.300 | 0.250 | 0.250 | 0.231 |
Dividend Growth | - | - | 20.00% | - | 8.32% | 20.02% |
Gross Margin | 31.74% | 31.75% | 30.96% | 31.61% | 29.70% | 28.83% |
Operating Margin | 20.66% | 20.58% | 19.31% | 19.22% | 17.18% | 15.09% |
Profit Margin | 18.45% | 18.73% | 13.53% | 19.25% | 18.55% | 14.47% |
Free Cash Flow Margin | 17.70% | 16.04% | 10.24% | 9.22% | 9.30% | 11.73% |
EBITDA | 251.71 | 247.41 | 221.12 | 200.12 | 157.07 | 127.77 |
EBITDA Margin | 26.32% | 26.24% | 25.05% | 23.84% | 22.30% | 20.72% |
D&A For EBITDA | 54.09 | 53.41 | 50.69 | 38.78 | 36.06 | 34.68 |
EBIT | 197.62 | 194 | 170.43 | 161.34 | 121.01 | 93.08 |
EBIT Margin | 20.66% | 20.58% | 19.31% | 19.22% | 17.18% | 15.09% |
Effective Tax Rate | 12.98% | 12.84% | 15.33% | 11.41% | 4.01% | 11.53% |
Revenue as Reported | - | - | 882.57 | 839.26 | 704.53 | 616.71 |
Advertising Expenses | - | - | 0.97 | 0.86 | 0.64 | 0.44 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.